Alka-Seltzer Plus needs more time to re-label
This article was originally published in The Tan Sheet
Bayer HealthCare asks FDA for more time to change packaging for its cold and flu relief line to comply with a final rule for labeling acetaminophen products. Thirteen stock-keeping units under the Alka-Seltzer Plus brand will be unable to accommodate organ-specific warnings by the rule's effective date of April 29, Bayer says in a Feb. 16 1letter to the agency. The firm's VP of Regulatory Affairs Leonard Baum explains, "Bayer was forced to wait" for FDA's technical amendment of Nov. 25, 2009, which clarified that smaller immediate containers such as blister cards and sachets must bear liver injury and stomach bleeding warnings (2"The Tan Sheet" Nov. 30, 2009). Bayer asks for a 12-month deferral to re-label ASP foil pouches and stick packs, and a six-month deferral to re-label the companion cartons. A spokeswoman said the company has not yet heard from FDA
You may also be interested in...
Acetaminophen products sold in stick packs and sachets must carry warnings about the risk of liver injury by April 29, 2010, a technical amendment to the final rule for internal analgesics says
The entry of India’s state-owned Indian Immunologicals and partner Griffith University in the COVID-19 vaccine race could potentially disrupt pricing dynamics. The alliance is developing a live-attenuated, single dose vaccine, which it hopes will be ready for launch in 18-24 months.
Shortly after wrapping up a Phase III trial for its proposed generic Advair Diskus product in the US, Cipla has won FDA approval for the first generic Proventil HFA product, as it continues to build up steam in the US respiratory market.